ArriVent BioPharma, Inc. Common Stock Asset Resilience Ratio
ArriVent BioPharma, Inc. Common Stock asset resilience ratio. ArriVent BioPharma, Inc. Common Stock (AVBP) has an Asset Resilience Ratio of 55.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AVBP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ArriVent BioPharma, Inc. Common Stock (2023–2025)
Asset resilience ratio of ArriVent BioPharma, Inc. Common Stock from 2023 to 2025. This chart shows how ArriVent BioPharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read ArriVent BioPharma, Inc. Common Stock (AVBP) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ArriVent BioPharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of ArriVent BioPharma, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $218.44 Million | 55.34% |
| Total Liquid Assets | $218.44 Million | 55.34% |
Asset Resilience Insights
- Very High Liquidity: ArriVent BioPharma, Inc. Common Stock maintains exceptional liquid asset reserves at 55.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ArriVent BioPharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare ArriVent BioPharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
ArriVent BioPharma, Inc. Common Stock Asset Resilience Ratio by Year (2023–2025)
ArriVent BioPharma, Inc. Common Stock asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for ArriVent BioPharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 80.22% | $267.28 Million | $333.17 Million | +27.64pp |
| 2024-09-30 | 52.58% | $144.57 Million | $274.94 Million | -- |
| 2023-09-30 | 0.00% | $0.00 | $163.10 Million | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more